Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daratumumab-based therapy works in treating patients
with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes
daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a
monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Bortezomib is a drug that prevents myeloma cells from getting rid of their waste products,
leading to being targeted for death. Dexamethasone is a steroid that is commonly used, either
alone or in combination with other drugs, to treat multiple myeloma. Lenalidomide and
thalidomide may stop the growth of multiple myeloma by blocking the growth of new blood
vessels necessary for tumor growth. Giving daratumumab, bortezomib, dexamethasone, and
thalidomide or lenalidomide may be a good way to treat patients with newly diagnosed multiple
myeloma with kidney failure.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI)